---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-032176"
form_type: "8-K"
ticker: "APUS"
cik: "0001894525"
company_name: "Apimeds Pharmaceuticals US, Inc."
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T15:01:17.334243+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Apimeds amends bylaws: reduces quorum, eliminates written consent, raises bar for director removal

## Summary
- Quorum reduced from majority to 33 1/3% of outstanding shares.
- Stockholders can no longer act by written consent; removal of directors is for cause only with 66 2/3% vote.
- Advanced notice required for stockholder proposals and director nominations.
- Board size fixed between 1 and 7 directors; Delaware forum selection clause added.
- Amendments to bylaws require affirmative vote of 66 2/3% of voting power.

## SEC filing metadata
- accession: 0001213900-25-032176
- form_type: 8-K
- ticker: APUS
- cik: 0001894525
- company_name: Apimeds Pharmaceuticals US, Inc.
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894525/000121390025032176/0001213900-25-032176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894525/000121390025032176/ea0238443-8k_apimeds.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-032176
- JSON: https://secwatch.observer/filing/0001213900-25-032176.json
- Plain text: https://secwatch.observer/filing/0001213900-25-032176.txt

## Key facts
- Governance Changes
  Apimeds Pharmaceuticals US, Inc.: Amended bylaws to add advance notice procedures, restrict special meetings, reduce quorum to 33 1/3%, eliminate written consent, set board size range, limit director removal to cause with 66 2/3% vote, require 66 2/3% vote to amend bylaws, and add Delaware forum selection clause (effective 2025-04-11).
  - Change: bylaw amendment
  - Effective: 2025-04-11
  source text: On April 11, 2025, the Board of Directors (the “Board”) of Apimeds Pharmaceuticals US, Inc. (the “Company”) amended its bylaws to, among other things: (i) establish an advanced notice procedure for stockholder proposals and director nominations to be brought before an annual or special meeting of stockholders (Section 5); (ii) limit the circumstances under which a special meeting of the stockholders can be convened (Section 6(a)); (iii) reduce the quorum requirement to transact business at a meeting of the stockholders from a majority, to 33 1/3% of the outstanding shares of stock entitled to vote (Section 8); (iv) eliminate the ability of stockholders to act by written consent (Section 13); (v) set the range of the number of directors constituting the whole Board to not less than one and not more than seven in number (Section 15); (vi) limit the removal of directors to removal for cause only, requiring the affirmative vote of at least 66 2/3% of the voting power of all outstanding sha
  evidence_url: https://www.sec.gov/Archives/edgar/data/1894525/000121390025032176/0001213900-25-032176-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.